CN113491643B

CN113491643B - Antipruritic use of angiogenin

Info

Publication number: CN113491643B
Application number: CN202010201784.XA
Authority: CN
Inventors: 顾建斐; 胡坚生; 王顾莫环; 胡国富
Original assignee: Huzhou Meiyide Biotechnology Co ltd
Current assignee: Huzhou Meiyide Biotechnology Co ltd
Priority date: 2020-03-20
Filing date: 2020-03-20
Publication date: 2024-04-12
Anticipated expiration: 2040-03-20
Also published as: CN113491643A

Abstract

The invention provides an antipruritic application of angiogenin, in particular to an antipruritic product containing angiogenin, which can effectively relieve itching, has quick response and almost no side effect; but also can effectively inhibit skin itch caused by various reasons or different reasons, including allergic skin itch or skin itch caused by excessive irradiation of sunlight or ultraviolet light; in addition, the antipruritic product provided by the invention not only has the antipruritic function, but also has the effects of resisting wrinkles and reducing spots, and is especially suitable for people with sensitive skin.

Description

Antipruritic use of angiogenin

Technical Field

The invention relates to the field of cosmetics, in particular to an antipruritic application of angiogenin and an antipruritic product containing the angiogenin.

Background

Under normal conditions, the moisture is not easy to run off due to the water absorption function and the barrier function of the stratum corneum and the covering function of lipid substances secreted by sweat glands and sebaceous glands, the stratum corneum can keep a certain moisture content, the moisture of the stratum corneum is increased and kept, and the skin can keep soft and elastic. There are two main causes of skin dryness due to the lack of water in the stratum corneum: firstly, the weather is dry, and the relative humidity is low; secondly, the normal water absorption and barrier function of the skin are impaired.

Factors such as diet and environment can cause skin itch, and especially, certain individuals with sensitive skin are more prone to skin itch. In modern society, some people who use cosmetics often induce skin irritation, inflammation, allergy, and itching due to the use of cosmetics.

Current treatment or alleviation of itch mainly comprises: antihistamines, antiallergic agents, etc. as oral agents, antihistamines, adrenocortical steroids, nonsteroidal antiinflammatory agents, etc. as external agents. However, when the oral preparation is used, a clinical effect takes a certain time and problems such as side effects (sleepiness, burnout feeling) to the central nervous system, damage to the digestive system, etc. may occur. On the other hand, when external preparations are used, the antipruritic effect is insufficient, and particularly, when steroid preparations are used for a long period of time, there are side effects such as a decrease in adrenal function, steroid acne, and the like.

Therefore, there is an urgent need in the art to develop antipruritic products that are safe to use, have few side effects, and are fast and effective.

Disclosure of Invention

The invention aims to provide an antipruritic product which is safe in use, small in side effect, quick and effective and application thereof in the aspect of antipruritic. The antipruritic product of the present invention contains angiogenin as an antipruritic ingredient.

The invention provides an application of angiogenin in preparing antipruritic products.

In another preferred embodiment, the antipruritic product is a cosmetic composition.

In another preferred embodiment, the antipruritic product is further used for one or more uses selected from the group consisting of: crease resistance, speckle reduction and whitening.

In another preferred embodiment, the effective concentration of the angiogenin is from 0.000001% to 0.1% of the total weight.

In another preferred embodiment, the effective concentration of the angiogenin is from 0.000001% to 0.001% of the total weight.

In another preferred embodiment, the effective concentration of the angiogenin is from 0.000001% to 0.00001% of the total weight.

In another preferred embodiment, the antipruritic product is used for inhibiting or alleviating skin itch.

In another preferred embodiment, the itch comprises a itch of skin caused by a factor selected from the group consisting of: allergic skin itch, ordinary skin itch, eczematous itch, or combinations thereof.

In another preferred example, the common skin itch includes itch caused by dry skin.

In another preferred embodiment, the pruritus comprises systemic pruritus and localized pruritus.

In another preferred embodiment, the skin itch occurs at a location selected from the group consisting of: facial, neck, back, chest, abdomen, limbs, waist, or a combination thereof.

In another preferred embodiment, the skin itch is allergic skin itch.

In another preferred embodiment, the skin itch is allergic skin itch without inflammation and/or redness.

In another preferred example, the skin itch is allergic skin itch accompanied by inflammation and/or redness and swelling.

In another preferred example, the skin itch is allergic skin itch accompanied by inflammation and/or redness and occurring on the face or neck.

In another preferred example, the skin itch is skin itch caused by irradiation of sunlight or Ultraviolet (UV).

In another preferred embodiment, the antipruritic product is suitable for people with sensitive skin.

In another preferred embodiment, the skin sensitivity refers to dryness, redness, spotting, redness, desquamation, or sores on the skin surface.

In another preferred embodiment, the angiogenin is human angiogenin.

In another preferred embodiment, the human angiogenin is recombinant human angiogenin.

In another preferred embodiment, the recombinant human angiogenin is methionine at its N-terminus and has a sequence as set forth in SEQ ID NO: 2.

In another preferred embodiment, the angiogenin is prepared by the steps of:

(a) Culturing a host cell under conditions suitable for expression of the angiogenin, thereby expressing the angiogenin, wherein the host cell comprises a vector for expression of the angiogenin, and the vector comprises a DNA sequence encoding the angiogenin; and (b) isolating and purifying the angiogenin expressed in step (a).

In another preferred embodiment, the antipruritic product is a liquid composition, a paste composition, a gel composition, or a spray.

In another preferred embodiment, the antipruritic product is selected from the group consisting of: cream, lotion, cream, sun cream, facial mask, toner, eye cream, massage cream, and hand cream.

In another preferred embodiment, the antipruritic product is formulated as a cream or a facial mask.

In another preferred embodiment, the antipruritic product (or antipruritic composition) does not contain skin irritant components.

In another preferred embodiment, the stimulating ingredient is selected from the group consisting of: alcohol, hormone, fruit acid, phenoxyethanol and heavy metals.

In another preferred embodiment, the antipruritic product further comprises a substance selected from the group consisting of: an ultraviolet light absorber, an ultraviolet light diffuser, a toner, or a mixture thereof.

In another preferred embodiment, the antipruritic product contains additional ingredients selected from the group consisting of: water, glycerol, yeast extract, hamamelis virginiana (HAMAMELIS VIRGINIANA) extract, cucumber (cucumber SATIVUS) fruit extract, chamomile (CHAMOMILLA RECUTITA) flower extract, fucus vesiculosus (FUCUS VESICULOSUS) extract, paeonia lactiflora (PAEONIA ALBIFLORA) root extract, sodium hyaluronate, and xanthan gum.

In another preferred embodiment, the antipruritic product is applied directly to or around the itchy area of the skin.

It is understood that within the scope of the present invention, the above-described technical features of the present invention and technical features specifically described below (e.g., in the examples) may be combined with each other to constitute new or preferred technical solutions. And are limited to a space, and are not described in detail herein.

Drawings

FIG. 1 is a graph showing the effect of a patient with refractory itching of unknown cause of the back and waist before, after Tu Yizhou and after 2 weeks of continuous application of skin cream comprising recombinant ANG.

Figure 2 is a graph of the effect of patient b on redness, swelling and itching of the face before and after 3 days of continuous application of skin cream comprising recombinant ANG.

Detailed Description

The present inventors have made extensive and intensive studies and, for the first time, have unexpectedly found that angiogenin has an antipruritic function, and when an effective amount of angiogenin is applied to the itchy part of the skin or around it, it is effective not only in antipruritic but also fast in onset of action with almost no side effects. Experiments show that the angiogenin not only can inhibit, relieve and eliminate skin itch, but also can effectively improve symptoms such as skin redness, swelling, inflammation and the like at or around the itch. On this basis, the present invention has been completed.

Specifically, the antipruritic product of the invention can not only inhibit, relieve and eliminate common skin itch, but also effectively inhibit skin itch caused by various reasons or different reasons, including allergic skin itch (such as cosmetic allergic skin itch), skin itch caused by excessive irradiation of sunlight or ultraviolet light. In addition, the antipruritic product can effectively treat and relieve skin itch and simultaneously can effectively improve skin problems such as skin aging, pigmentation and the like.

Angiogenin

As used herein, "angiogenin," "polypeptide ANG protein," and "ANG" are used interchangeably to refer to angiogenin from a mammal, including wild-type and mutant angiogenin. The preferred angiogenin is human angiogenin. The term includes recombinant or non-recombinant produced human angiogenin, preferably ANG prepared by recombinant methods.

In the present invention, the antipruritic active ingredient is angiogenin, preferably human angiogenin, more preferably recombinant human angiogenin.

Human Angiogenin (Angiogenin) is a protein composed of 123 amino acids, the N-terminal of recombinant human Angiogenin is added with one methionine, the protein is composed of 124 amino acids, and the amino acid sequence of the protein is SEQ ID NO. 2:

MQDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRRP。

human angiogenin is a secreted, water-soluble protein with isoelectric point greater than 10. Angiogenin is present in normal human blood and is typically present in an amount of 250-360ng/ml.

The main physiological function of angiogenin is to stimulate angiogenesis under specific conditions, and maintain normal function of blood vessels in vivo. Since metabolism of various organs and tissues in the body requires blood circulation to transport oxygen and nutrients, exhaust gas and waste materials are removed, angiogenin plays an important role in maintaining normal physiological functions of various tissues and organs in the body.

In addition to the primary effect of stimulating angiogenesis, angiogenin can inhibit Melanocyte (Melanocyte) on skin surface from secreting melanin, thereby having anti-wrinkle whitening effect. Meanwhile, angiogenin can promote melanocyte, fibroblast (Fibroblasts), keratinocytes (Keratinocytes) and epidermal Cells (Epithelial Cells) to secrete Collagen (Collagen) and Elastin (Elastin) so as to have the effects of preventing skin aging and increasing skin elasticity.

Angiogenin is present in milk in addition to normal human blood. Human angiogenin can be isolated from human plasma or from human tumor cell culture supernatant. Bovine angiogenin can be isolated from milk. Human angiogenin can also be prepared by genetic engineering methods. The human angiogenin prepared by the genetic engineering method is compared with the angiogenin naturally generated in human body, and the physicochemical property and the biological activity are completely the same.

Preparation of angiogenin

In the present invention, angiogenin is preferably prepared by recombinant methods. A preferred method comprises the steps of:

(a) Culturing a host cell under conditions suitable for expression of angiogenin, thereby expressing angiogenin, wherein the host cell comprises a vector that expresses angiogenin, the vector comprising the sequence of SEQ ID NO:1, a DNA sequence encoding an angiogenin, SEQ ID NO: the atgcaagcaagccagcaagcaactcagcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcagctgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactgcaactctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctctct a. The invention relates to a method for producing a fibre-reinforced plastic composite a. The invention relates to a method for producing a fibre-reinforced plastic composite.

(b) Isolating and purifying the angiogenin expressed in step (a).

In a preferred embodiment, the DNA molecule encoding an angiogenin used is engineered according to the codon preference of the host cell of choice. A specific coding sequence is shown in SEQ ID NO: 1.

Antipruritic products

The active ingredient of the antipruritic product of the present invention is angiogenin, preferably human angiogenin, more preferably recombinant human angiogenin. Typically, in the antipruritic products of the present invention, the effective concentration of angiogenin is 0.000001% to 0.1% or more of the total weight. Of course, the concentration of angiogenin may also be higher than 0.1% because this still has an antipruritic effect. From the viewpoint of production costs, the effective concentration of angiogenin is preferably 0.000001% to 0.001%, more preferably 0.000001% to 0.0001%, most preferably 0.000001% to 0.00001% by weight based on the total weight.

The angiogenin used in the present invention may be in a native or recombinant form, preferably in a recombinant form. The angiogenin used in the present invention is preferably purified, for example, greater than 80% pure, preferably greater than 90%, more preferably greater than 95%, most preferably greater than 99% angiogenin.

In addition to containing angiogenin as a main active ingredient, other ingredients known in the art, such as arbutin (Albutin), kojic acid, hydrogenated casein, bovine angiogenin, or a mixture thereof, may be contained in the antipruritic product of the present invention.

In addition, the antipruritic products of the present invention may further include additives commonly used in the art, such as fragrances, essential oils, stabilizers, moisturizers, vitamins, essential fatty acids, lipophilic sunscreens, liposoluble polymers, and the like. Of course, the person skilled in the art will carefully choose the optional additive compounds and/or their amounts such that the advantageous properties of the angiogenin according to the invention are not or substantially not impaired by these additives.

The antipruritic products of the present invention may be formulated in various formulations commonly known in the art, such as creams, lotions, creams, facial washes, sunscreens, facial masks, lotions, eye creams, massage creams, hand creams or other cosmetics for the face, neck, hands and body.

The antipruritic product of the invention can be directly applied to the skin or applied to the skin when in use.

The invention has the main advantages that:

1. angiogenin can inhibit, relieve and eliminate skin itch very rapidly, and has no side effects;

2. the angiogenin not only can inhibit, relieve and eliminate common skin itch, but also can effectively inhibit skin itch caused by various reasons or different reasons, including allergic skin itch or skin itch caused by excessive irradiation of sunlight or ultraviolet light;

3. the antipruritic product provided by the invention not only has the antipruritic function, but also has the effects of resisting wrinkles and reducing spots, and is especially suitable for people with sensitive skin.

The invention will be further illustrated with reference to specific examples. It is to be understood that these examples are illustrative of the present invention and are not intended to limit the scope of the present invention. The experimental methods, in which specific conditions are not noted in the following examples, are generally conducted under conventional conditions or under conditions recommended by the manufacturer. Percentages and parts are weight percentages and parts unless otherwise indicated.

EXAMPLE 1 quick antipruritic action of ANG

The experimental object: 20 volunteers with mild or moderate itching (no redness) and 12 men and 8 women, aged 40 to 60 years, were randomized into 2 groups with the same number of men and women in the experimental and control groups.

The 20 volunteers had skin pruritus caused by allergy, dryness and unknown reasons, respectively, and the skin pruritus sites included: face, neck, back, waist, legs, arms. The cause of pruritus is not distinguished at the time of grouping.

All volunteers had no other systemic disease and had no antibiotics or immunosuppressants taken in the last month.

In selecting the volunteers, the degree of cutaneous pruritus of each volunteer candidate was discriminated according to the degree of quaternary pruritus (no pruritus, mild pruritus, moderate pruritus, and severe pruritus) of subjective judgment of the volunteer candidate, and a total of 20 volunteer candidates of the degree of cutaneous pruritus, mild pruritus and moderate pruritus were selected as the test subjects of this example.

The test subjects did not use topical steroids for a week prior to the start of the experiment, and the period of the experiment limited the use of topical steroids, nor had other antipruritic substances been used.

For the test group, a skin cream containing recombinant human angiogenin (0.00001% of the total weight of recombinant human angiogenin) was applied to the itchy part of skin or around it once.

For the control group, a skin cream containing no recombinant human angiogenin and the rest of the same composition was applied to the itchy part of the skin or around it once.

Skin itch was scored by each volunteer as to the extent of itch as in table 1, 5 minutes prior to application, and included statistics for mild or moderate itch.

The skin itch was scored again by each volunteer as in table 2 30 minutes after application.

TABLE 1 division of the degree of itching

Degree of itching	Standard of
		No itching	Subjective feeling of no skin itching
Slight itching	Subjective feeling of slight skin itching
		Moderate itching	Subjective feeling of skin itching, and the skin itching is bearable
Severe itching	Subjective feeling of skin itching, and the skin itching is not bearable

TABLE 2 evaluation of the degree of improvement of pruritus

The statistical results are shown in table 3 below:

TABLE 3 Table 3

Control group	Test set
		4 X0 (person)	4 X5 (person)
3 X0 (person)	3 X2 (person)
		2 X3 (person)	2 X2 (person)
1 X7 (person)	1 X1 (person)
		Total score = 13 points	Total score = 31 score

The test results show that ANG was able to rapidly, significantly inhibit and alleviate skin itching in the control group, and to reduce to no itching in 70% of the subjects tested, compared to the control group.

Example 2ANG has a remarkable antipruritic effect on itching with redness and swelling

The experimental object: 10 volunteers with red and swollen itching, 2 men and 8 women, aged from 20 years to 45 years, were randomly divided into 2 groups, and the number of men and women was the same in the experimental group and the control group.

The red and swollen sites of 10 volunteers all included: a face or neck.

In selecting volunteers, the degree of cutaneous pruritus of each volunteer candidate was differentiated according to the degree of quaternary pruritus (no pruritus, mild pruritus, moderate pruritus, and severe pruritus) as subjective judgment of the volunteer candidate. Meanwhile, according to the face or neck red and swollen area scores of the volunteer candidate as four grades (no red and swollen, mild red and swollen, moderate red and swollen, severe red and swollen), 10 volunteer candidate with the skin itching degree of mild itching and moderate itching and the skin red and swollen degree of mild red and moderate red and swollen were selected as test subjects.

For the test group, a skin care product containing recombinant human angiogenin (skin cream, containing 0.00005% of recombinant human angiogenin by total weight) was applied to the red swelling portion of skin or its periphery twice daily, once a day in the morning and in the evening for a total of 3 days.

For the control group, the skin care product containing no recombinant human angiogenin and having the same components was applied to the itching area of the skin accompanied by red swelling or its surroundings twice daily, once a day in the morning and at night for a total of 3 days.

Prior to application, skin itchiness was scored by each volunteer as to the extent of itchiness according to table 1 (example 1), and statistics were included for mild or moderate itchiness. Meanwhile, skin redness and swelling was scored by each volunteer according to table 4, and statistics were included for mild redness or moderate redness.

Skin redness and swelling and itching were scored again by each volunteer as in table 5 3 days after application.

TABLE 4 division of the degree of redness and swelling

TABLE 5 evaluation of the degree of improvement of redness and swelling and itching

The statistical results are shown in table 6 below:

TABLE 6

Test results show that, compared with a control group, the ANG can not only remarkably inhibit and relieve skin itch, but also remarkably eliminate skin redness and swelling at or around the itching part, and the skin itch effect of 80% of test subjects (4/5) is remarkable.

EXAMPLE 3 antipruritic effect of ANG on skin itch caused by sunlight or Ultraviolet (UV) irradiation

The experimental object: skin itch was scored according to the degree of itch in table 1, and 4 volunteers with skin itch caused by irradiation of sunlight (seaside) for 1 hour at moderate itch were included, and men 2, women 2, were randomly divided into 2 groups, and the number of men and women in the experimental group and the control group was the same.

The skin itching sites include: face, neck and back.

For the test group, a skin cream containing recombinant human angiogenin (0.00001% of the total weight of recombinant human angiogenin) was applied to the face, neck and back 2 times daily for a total of 2 days.

For the control group, a skin cream containing no recombinant human angiogenin and the other components were applied to the itchy face of the skin 2 times daily for a total of 2 days on the neck and back.

Skin itch was scored again by each volunteer as in table 2 after 2 days of application.

The statistical results are shown in table 7 below:

TABLE 7

Control group	Test set
		4 X0 (person)	4 X1 (person)
3 X0 (person)	3 X1 (person)
		2 X1 (person)	2 X0 (person)
1 X1 (person)	1 X0 (person)
		Total score = 3 points	Total score = 7 points

The test results show that ANG can significantly inhibit and alleviate skin itch caused by excessive irradiation of sunlight or Ultraviolet (UV) in the test group to which ANG is applied, compared with the control group, for skin itch caused by irradiation of sunlight or UV.

Example 4 antipruritic product containing angiogenin (ANG skin cream)

In this example, the antipruritic component in the formulation of ANG skin cream is ANG polypeptide (recombinant human angiogenin) with a content of 0.00001% of total weight of skin cream. Other components of the ANG skin cream comprise: polyacryl dimethyl taurate, hydrogenated polydecene and tridecyl alcohol polyethers, olive oil cetyl and sorbitan olive oleate, glycerol stearate/polyethylene glycol stearate, cetostearyl alcohol, caprylic/capric triglyceride, isohexadecane, alpha-tocopherol acetate, propylene glycol, hydroxyacetone, phenoxyethanol/ethylhexyl glycerol, chlorobenzeneglycolether/1, 3 butylene glycol, carrageenan extracts, phenoxyethanol, glycosyltrehalose and water (in appropriate amounts).

Example 5 antipruritic product containing angiogenin (biofiber ANG mask)

In this example, a bio-fiber ANG mask (including mask patches and essence) was prepared, wherein the itching relieving component of the essence was ANG polypeptide (recombinant human angiogenin) in an amount of 0.00001% of the total weight of the skin cream. Other components in the biological fiber ANG mask essence comprise: water (in an appropriate amount), butylene glycol, glycerin, propylene glycol, yeast extract, betaine, witch hazel (HAMAMELIS VIRGINIANA) extract, cucumber (cucure SATIVUS) fruit extract, chamomile (CHAMOMILLA RECUTITA) flower extract, fucus (FUCUS VESICULOSUS) extract, beta-glucan, trehalose, dipropylene glycol, p-hydroxyacetophenone, sodium hyaluronate, sclerotium (SCLEROTIUM ROLFSSII) gum, xanthan gum, caprylyl glycol, dipotassium glycyrrhizinate, disodium EDTA.

The antipruritic product is prepared according to the conventional conditions in the field.

EXAMPLE 6 antipruritic effect of ANG on itching in patients of unknown cause (case one)

Patient: first (female) aged 55 years

Symptoms: intractable pruritus caused by unknown lumbar and back

Antipruritic treatment: ANG skin cream (example 4) was applied to the itchy part and the effect was observed

Taking an appropriate amount of ANG skin cream, lightly applying the ANG skin cream on the itching part of the waist and back and the periphery, and eliminating itching after 10 minutes. On day 2, itching was reproduced, but was reduced compared to that before the first application of the skin cream containing ANG, and after 10 minutes, itching was lost after the continued application of the ANG cream. Continuously applying for 1 week, 1-2 times daily, and recovering the patient basically; the application was continued for 2 weeks, and the recovery was recovered.

The results of the comparison of the itchy areas before and after application of the skin cream comprising recombinant ANG are shown in fig. 1.

Example 6 antipruritic effect of ANG on patients with facial redness, swelling and itching (case two)

Patient: yi certain (female), age 35

Symptoms: red, swelling and itching of the face

Antipruritic treatment: ANG skin cream (example 4) was applied to the itchy area and the effect was observed.

An appropriate amount of ANG cream was gently applied to and around the red and swollen region of the face, once a day, each morning and evening, for 3 days continuously, and the patient was substantially healed, and the results of the comparison of red, swollen and itchy regions before and after the application of the cream comprising recombinant ANG cream were shown in FIG. 2.

All documents mentioned in this application are incorporated by reference as if each were individually incorporated by reference. Further, it will be appreciated that various changes and modifications may be made by those skilled in the art after reading the above teachings, and such equivalents are intended to fall within the scope of the claims appended hereto.

Sequence listing

<110> Huzhou Mei Yi Biotech Co Ltd

<120> antipruritic use of angiogenin

<130> P2019-1702

<160> 2

<170> SIPOSequenceListing 1.0

<210> 1

<211> 372

<212> DNA

<213> Artificial sequence (artificial sequence)

<400> 1

atgcaggata actccaggta cacacacttc ctgacccagc actatgatgc caaaccacag 60

ggccgggatg acagatactg tgaaagcatc atgaggagac ggggcctgac ctcaccctgc 120

aaagacatca acacatttat tcatggcaac aagcgcagca tcaaggccat ctgtgaaaac 180

aagaatggaa accctcacag agaaaaccta agaataagca agtcttcttt ccaggtcacc 240

acttgcaagc tacatggagg ttccccctgg cctccatgcc agtaccgagc cacagcgggg 300

ttcagaaacg ttgttgttgc ttgtgaaaat ggcttacctg tccacttgga tcagtcaatt 360

ttccgtcgtc cg 372

<210> 2

<211> 124

<212> PRT

<213> Artificial sequence (artificial sequence)

<400> 2

Met Gln Asp Asn Ser Arg Tyr Thr His Phe Leu Thr Gln His Tyr Asp

1 5 10 15

Ala Lys Pro Gln Gly Arg Asp Asp Arg Tyr Cys Glu Ser Ile Met Arg

20 25 30

Arg Arg Gly Leu Thr Ser Pro Cys Lys Asp Ile Asn Thr Phe Ile His

35 40 45

Gly Asn Lys Arg Ser Ile Lys Ala Ile Cys Glu Asn Lys Asn Gly Asn

50 55 60

Pro His Arg Glu Asn Leu Arg Ile Ser Lys Ser Ser Phe Gln Val Thr

65 70 75 80

Thr Cys Lys Leu His Gly Gly Ser Pro Trp Pro Pro Cys Gln Tyr Arg

85 90 95

Ala Thr Ala Gly Phe Arg Asn Val Val Val Ala Cys Glu Asn Gly Leu

100 105 110

Pro Val His Leu Asp Gln Ser Ile Phe Arg Arg Pro

115 120

Claims

1. Use of angiogenin for the preparation of an antipruritic product; the antipruritic product is used for inhibiting or relieving skin itch;

wherein the angiogenin is human angiogenin; and the N-terminal of the angiogenin is methionine, and the amino acid sequence of the angiogenin is shown in SEQ ID NO: 2.

2. The use according to claim 1, wherein the antipruritic product is used simultaneously for one or more uses selected from the group consisting of: crease resistance, speckle reduction and whitening.

3. The use according to claim 1, wherein the effective concentration of angiogenin is from 0.000001% to 0.1% of the total weight.

4. The use of claim 1, wherein said itch comprises a itch of skin caused by a factor selected from the group consisting of: allergic skin itch, ordinary skin itch, eczematous itch, or combinations thereof.

5. The use according to claim 1, wherein said skin itch occurs at a location selected from the group consisting of: facial, neck, back, chest, abdomen, limbs, waist, or a combination thereof.

6. The use according to claim 1, wherein the skin itch is allergic skin itch accompanied by inflammation and/or redness and occurring on the face or neck.

7. The use according to claim 1, wherein the skin itch is a skin itch caused by irradiation of sunlight or ultraviolet light (UV).

8. The use according to claim 1, wherein the antipruritic product is a liquid composition, a paste composition, a gel composition, or a spray.

9. The use according to claim 1, wherein the antipruritic product is selected from the group consisting of: cream, lotion, cream, facial mask, toner.

10. The use according to claim 1, wherein the antipruritic product comprises additional ingredients selected from the group consisting of: water, glycerol, yeast extract, hamamelis virginiana (HAMAMELIS VIRGINIANA) extract, cucumber (cucumber SATIVUS) fruit extract, chamomile (CHAMOMILLA RECUTITA) flower extract, fucus vesiculosus (FUCUS VESICULOSUS) extract, paeonia lactiflora (PAEONIA ALBIFLORA) root extract, sodium hyaluronate, and xanthan gum.

11. The use according to claim 1, wherein the antipruritic product further comprises a substance selected from the group consisting of: an ultraviolet light absorber, an ultraviolet light diffuser, a toner, or a mixture thereof.

12. Use according to claim 9, wherein the cream is selected from the group consisting of: sun cream, eye cream, massage cream, and hand cream.